CUL4A and plasma cell myeloma: By contrast, in the presence of lenalidomide, a thalidomide analogue that is used for treating multiple myeloma, CUL4A/B-DDB1-CRBN was induced to acquire the capacity to catalyse the selective ubiquitination and degradation of two lymphoid transcription factors55, 56.